{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:42:25Z","timestamp":1785825745751,"version":"3.56.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32DK007727"],"award-info":[{"award-number":["T32DK007727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K23DK105229"],"award-info":[{"award-number":["K23DK105229"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R03DK118314"],"award-info":[{"award-number":["R03DK118314"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"The Netherlands Organisation for Health Research and Development","doi-asserted-by":"crossref","award":["113202001"],"award-info":[{"award-number":["113202001"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Crocokids"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WI213008"],"award-info":[{"award-number":["WI213008"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011684","name":"Crohn's Colitis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018353","name":"ECCO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The use of concomitant azathioprine may improve efficacy and pharmacokinetic (PK) properties of infliximab (IFX) but is also associated with an increased risk of adverse events. Proactive therapeutic drug monitoring (pTDM) of IFX monotherapy is an alternative strategy to improve PK. The aim of this study was to evaluate whether IFX with an immunomodulator (combo) has PK benefits over IFX-pTDM (mono) in pediatric Crohn\u2019s disease (CD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This PK analysis included pediatric CD patients who started either IFX combo (TISKids study) or IFX mono with pTDM (REFINE cohort). Combo and mono IFX trough levels (TLs) and antibodies-to-infliximab were assessed at infusion 3, 4, and 5. A population PK model was built to compare IFX PK outcomes (clearance [CL], TLs and cumulative exposure) between combo and mono groups at infusion 4 and 5. Clinical response and steroid-free clinical remission (SFCR) was assessed at infusion 4 and 5.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study included 128 pediatric CD patients (66 mono and 62 combo). At infusion 5, there was no significant difference between mono and combo median TLs 4.1 \u00b5g\/mL (2.1, 7.8) vs 5.9 \u00b5g\/mL (3.2, 9.4; P = .14) or median CL 0.26 L\/d (0.21, 0.32) vs 0.26 L\/d (0.21, 0.33; P = .81). Mono patients had a lower SFCR rate at infusion 5 (53% [31 of 59] vs 80% [32 of 40]; P = .01). Clinical response rates were significantly higher among combo than mono patients at both infusion 4 and 5.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study suggests that there are no PK differences (TLs and CL) between combo and mono therapy in pediatric CD patients who started IFX.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izad307","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T08:08:06Z","timestamp":1702109286000},"page":"1678-1685","source":"Crossref","is-referenced-by-count":8,"title":["Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn\u2019s Disease Exhibit Similar Pharmacokinetics"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-8570","authenticated-orcid":false,"given":"Ruben J","family":"Colman","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Stanford University School of Medicine , Stanford, CA ,","place":["USA"]},{"name":"Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism , Meibergdreef 9, Amsterdam ,","place":["the Netherlands"]},{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A","family":"Vuijk","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus MC-Sophia Children\u2019s Hospital , Rotterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A A","family":"Math\u00f4t","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy & Clinical Pharmacology, Amsterdam UMC, University of Amsterdam , Meibergdreef 9, Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Van Limbergen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology and Nutrition, Amsterdam University Medical Centers, University of Amsterdam, Emma Children\u2019s Hospital , Amsterdam ,","place":["the Netherlands"]},{"name":"Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism, University of Amsterdam , Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M E","family":"Jongsma","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus MC-Sophia Children\u2019s Hospital , Rotterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco W J","family":"Schreurs","sequence":"additional","affiliation":[{"name":"Department of Immunology, Erasmus MC , Rotterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4223-4211","authenticated-orcid":false,"given":"Phillip","family":"Minar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissy","family":"de Ridder","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus MC-Sophia Children\u2019s Hospital , Rotterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert R A M","family":"D\u2019Haens","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism , Meibergdreef 9, Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"issue":"3","key":"2025052401420612000_CIT0001","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology."},{"issue":"2","key":"2025052401420612000_CIT0002","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update","volume":"15","author":"van Rheenen","year":"2021","journal-title":"J Crohns Colitis."},{"issue":"7","key":"2025052401420612000_CIT0003","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther."},{"issue":"5","key":"2025052401420612000_CIT0004","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/apt.16733","article-title":"Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn\u2019s disease","volume":"55","author":"Colman","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"2025052401420612000_CIT0005","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe Ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology."},{"issue":"6","key":"2025052401420612000_CIT0006","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cpt.2148","article-title":"Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with Crohn\u2019s disease","volume":"109","author":"Xiong","year":"2021","journal-title":"Clin Pharmacol Ther."},{"issue":"12","key":"2025052401420612000_CIT0007","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00431-020-03750-0","article-title":"Infliximab in young paediatric IBD patients: it is all about the dosing","volume":"179","author":"Jongsma","year":"2020","journal-title":"Eur J Pediatr."},{"issue":"6","key":"2025052401420612000_CIT0008","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/MPG.0000000000002631","article-title":"Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations","volume":"70","author":"Winter","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"1","key":"2025052401420612000_CIT0009","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MPG.0000000000002112","article-title":"Causes of treatment failure in children with inflammatory bowel disease treated with infliximab: a pharmacokinetic study","volume":"68","author":"Naviglio","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"11","key":"2025052401420612000_CIT0010","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjy111","article-title":"Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease","volume":"12","author":"van Hoeve","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"8","key":"2025052401420612000_CIT0011","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis","volume":"17","author":"Colombel","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol. CLIN GASTROENTEROL H"},{"issue":"4","key":"2025052401420612000_CIT0012","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ibd\/izaa108","article-title":"Favorable outcomes and anti-TNF durability after addition of an immunomodulator for anti-drug antibodies in pediatric IBD patients","volume":"27","author":"Colman","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"15","key":"2025052401420612000_CIT0013","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med."},{"issue":"7","key":"2025052401420612000_CIT0014","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology."},{"key":"2025052401420612000_CIT0015","doi-asserted-by":"crossref","first-page":"3190548","DOI":"10.1155\/2018\/3190548","article-title":"The continental divide: Anti-TNF use in pediatric IBD is different in North America compared to other parts of the world","volume":"2018","author":"Church","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"8","key":"2025052401420612000_CIT0016","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology."},{"issue":"5","key":"2025052401420612000_CIT0017","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ibd.21844","article-title":"Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort","volume":"18","author":"Ashworth","year":"2012","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2025052401420612000_CIT0018","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/ibd\/izaa102","article-title":"Effect of a practice-wide anti-TNF proactive therapeutic drug monitoring program on outcomes in pediatric patients with inflammatory bowel disease","volume":"27","author":"Lyles","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2025052401420612000_CIT0019","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","article-title":"ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents","volume":"58","author":"Levine","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"1","key":"2025052401420612000_CIT0020","doi-asserted-by":"crossref","first-page":"e000123","DOI":"10.1136\/bmjgast-2016-000123","article-title":"Top-down infliximab study in kids with Crohn\u2019s disease (TISKids): an international multicentre randomised controlled trial","volume":"3","author":"Cozijnsen","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"2025052401420612000_CIT0021","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2020-322339","article-title":"First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn\u2019s disease: an open-label multicentre randomised controlled trial","volume":"71","author":"Jongsma","year":"2022","journal-title":"Gut."},{"issue":"S1","key":"2025052401420612000_CIT0022","first-page":"S344","article-title":"An evaluation of blood and stool biomarkers for deep remission in pediatric Crohn\u2019s disease identifies anti-TNF clearance as a vital biomarker of treatment response","volume":"75","author":"Bartel","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"2","key":"2025052401420612000_CIT0023","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/MIB.0000000000000284","article-title":"Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD","volume":"21","author":"Zitomersky","year":"2015","journal-title":"Inflamm Bowel Dis."},{"issue":"11","key":"2025052401420612000_CIT0024","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/apa.14008","article-title":"Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease","volume":"106","author":"Deora","year":"2017","journal-title":"Acta Paediatr."},{"issue":"3","key":"2025052401420612000_CIT0025","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/ijms18030575","article-title":"Serum-infliximab trough levels in 45 children with inflammatory bowel disease on maintenance treatment","volume":"18","author":"Rolandsdotter","year":"2017","journal-title":"Int J Mol Sci ."},{"issue":"9","key":"2025052401420612000_CIT0026","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3109\/00365521.2015.1027264","article-title":"The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease","volume":"50","author":"Hoekman","year":"2015","journal-title":"Scand J Gastroenterol."},{"issue":"10","key":"2025052401420612000_CIT0027","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2025052401420612000_CIT0028","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/ibd\/izz143","article-title":"Improved population pharmacokinetic model for predicting optimized infliximab exposure in pediatric inflammatory bowel disease","volume":"26","author":"Bauman","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"2025052401420612000_CIT0029","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/17512433.2021.2028619","article-title":"Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases","volume":"14","author":"Kantasiripitak","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"2025052401420612000_CIT0030","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/apt.15685","article-title":"Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn\u2019s disease","volume":"51","author":"Ungaro","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2025052401420612000_CIT0031","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1208\/s12248-016-9981-3","article-title":"Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade(R)","volume":"19","author":"Marini","year":"2017","journal-title":"AAPS J."},{"issue":"2","key":"2025052401420612000_CIT0032","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/MPG.0000000000001850","article-title":"The role of combination therapy in pediatric inflammatory bowel disease: a clinical report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition","volume":"66","author":"Day","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad307\/54950847\/izad307.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/10\/1678\/59547806\/izad307.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/10\/1678\/59547806\/izad307.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T05:42:24Z","timestamp":1748065344000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/10\/1678\/7505295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,1,3]]},"published-print":{"date-parts":[[2024,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izad307","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,1,3]]}}}